Foresight Mentors

Sonia Arrison

Sonia Arrison is a best-selling author, analyst, entrepreneur, and investor. She is founder of 100 Plus Capital, co-founder of Unsugarcoat Media (acquired by Medium), and associate founder and advisor to Singularity University in Mountain View, California. Her research focuses on exponentially growing technologies and their impact on society. Her most recent book, 100 Plus: How the Coming Age of Longevity Will Change Everything, From Careers and Relationships to Family and Faith, addresses the social, economic, and cultural impacts of radical human longevity. It gained national best-seller status and keeps Sonia busy speaking all over the world. Sonia is a Board Member at the Thiel Foundation, Foresight Institute, and Woodland School. She is also a Senior Fellow at the Fraser Institute in Vancouver, British Columbia, and author of two previous books (Western Visions and Digital Dialog). She was previously a Director and Senior Fellow in Tech Studies at the Pacific Research Institute and a columnist at TechNewsWorld.


Amir Banifatemi

General Manager XPRIZE

My general focus is on identifying and developing emerging and transformative initiatives that can impact society in significant and exponential ways. I do this by helping create interdisciplinary frameworks for understanding and planning new developments and the funding required to bring new innovations to market.

I have managed a few private and public technology investment and venture capital funds and know how to establish fund operations and their overall strategies and requirements.
I also help innovative ventures and startups that target products that could generate sustainable economic and societal impact. I help teams on product roadmap strategy, pricing and business model, fundraising, and high-growth partnerships and mergers. Particular emphasis on AI and predictive systems, Quantum technology, Genomics, and crowd economics.

Dr. Dina Radenkovic


I am a medical doctor, bioinformatics researcher and healthcare entrepreneur. My current roles as a Partner at the SALT Bio Fund & Chief Scientific Officer of HOOKE allow me to utilise my passion to help build companies that bring new piece of science or technology to the people with the aim of improving their health & longevity. My research at Hooke and at the Buck Institute is focused on standardising all novel surrogate biomarkers of aging and intervention that can help people live longer, happier and healthier lives by compressing th number of years spent in bad health (morbidity) and increasing helathy life expectancy. I workd at Guy’s and St Thomas’NHS Foundation Trust, qualified from UCL Medical School, London, UK and had research posts at Massachusetts General Hospital, Harvard, USA and King’s College London. My work is in the field of computational medicine focused on preventive cardiology and aging, but I also enjoy extending my research principles to a wider application of artificial intelligence in healthcare.



Stuart Armstrong

Aligned AI

My research at the Future of Humanity Institute centres on the safety and possibilities of Artificial Intelligence (AI), how to define the potential goals of AI and map humanity’s partially defined values into it, and the long term potential for intelligent life across the reachable universe. I’ve been working with people at the FHI and other organisations, such as DeepMind, to formalise AI desiderata in general models, so that AI designers can include these safety methods in their designs.

My past research interests include comparing existential risks in general, including their probability and their interactions, anthropic probability (how the fact that we exist affects our probability estimates around that key fact), decision theories that are stable under self-reflection and anthropic considerations, negotiation theory and how to deal with uncertainty about your own preferences, computational biochemistry, fast ligand screening, parabolic geometry, and my Oxford D. Phil. was on the holonomy of projective and conformal Cartan geometries.

Dr. Alexandra Bause


Alexandra is leading the venture creation programs that aim at founding new biotech startups targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies. Before joining Apollo Ventures, Alexandra worked with The Boston Consulting Group where she specialized in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.



Sourav Sinha

Longevity Vision Fund

Venture Partner, Head of Innovation
– Founder, CEO of Oncolinx
– Strategy at Celularity
– Forbes’ “30 Under 30: Healthcare”
– World Economic Forum Global Shaper
– Singularity University Global Solutions Program
– Dartmouth College


Arye Lipman


Arye is a General Partner at MarsBio, a seed stage venture fund based in Los Angeles, investing in deeptech and biotech companies. He holds a degree in Molecular and Cellular Biology from UCLA, and has a background in biotech R&D and drug development, entrepreneurship, and angel investing. He serves as a board member and advisor for various life sciences startups and accelerator programs in Southern California, including Empath Ventures, Lab Launch, and Larta Institute.



Ben Sun

Ben Sun is an experienced investor active with angel-stage companies in Silicon Valley, Asia and other parts of the world.  As a business executive, Ben is a market eco-system developer focused on technology and healthcare companies.

Ben has 20+ years of cross-border business experience in the fields of research, consulting, government, NGOs and investment. Earlier in his career, Ben was executive director of a China-based chapter of a global angel network.

Ben’s extensive range of business connections brings value to clients wishing to form market presence, distribution and technology support partnerships in Asia, Europe,  Latin America and the US.  Ben is expert in market entry planning, investment planning and funding solicitation.  As an advisor, Ben works with startups from UC Berkeley’s SkyDeck accelerator. He also advises private industry executives and teams in the San Francisco Bay Area. He has helped listed companies come into the US market.

Ben has developed insights and access to innovators in up-and-coming global trends through his work with angel groups across Asia, US and Europe.  He is a valued speaker at innovation conferences and judge at tech-pitch competitions.



Nils Regge, Apollo VC

Nils is a serial entrepreneur and company builder with a long-standing passion for health and biomedicine. At Apollo, Nils brings deal making skills, his impeccable business sense, and his expertise in growing early stage startups.

Nils founded company builder and investor TruVenturo in 2010, and he has taken part in over 30 financing rounds as an investor or co-founder among the companies he has cofounded. Of these, three have attained valuations over $100M, having attracted capital from top venture capital companies such as Insight Venture Partners, Highland Capital, and Harbourvest. Nils sits on the boards of multiple companies in his portfolio, helping to push them rapidly towards inflection points by focusing his teams towards only those activities that generate shareholder value. Nils has studied business in Hamburg and at UC Santa Barbara (UCSB) in California. He also completed the EO Entrepreneurial Master’s Program at MIT.

Dr. Jan Goetz, IQM Quantum Computers

Jan received his PhD on superconducting quantum circuits in 2017 from TU Munich and continued as a Postdoc in Helsinki at Aalto University. Helsinki is a great hub for quantum technology, which allowed him to receive a Marie-Curie Fellowship from the EU H2020 program. In addition, he has been working for the local Quantum Computer Project, where 8 research groups and the State Research Center VTT are co-developing a quantum processor. Based on these efforts and together with three co-founders, Jan has been spinning off a company, IQM Finland Oy. Since February 2019 he is the CEO of IQM and the company is now expanding their operations on the research campus in Espoo (Helsinki area). IQM’s is to developing a fast lane for quantum computer using innovative technology for 2nd generation quantum processors.

Andrew Scott, London Business School

Andrew J. Scott is Professor of Economics at London Business School having previously held positions at Oxford University, London School of Economics and Harvard University. His work focuses on the economics of longevity and he is the co-author of “The 100 Year Life” and “The New Long Life”. He was Managing Editor for the Royal Economic Society’s Economic Journal and Non-Executive Director for the UK’s Financial Services Authority 2009-2013. He is currently on the advisory board of the UK’s Office for Budget Responsibility, the Cabinet Office Honours Committee (Science and Technology), co-founder of The Longevity Forum, a member of the WEF council on Healthy Ageing and Longevity and a consulting scholar at Stanford University’s Center on Longevity. Andrew is also the recipient of an ESRC grant for researching the economic longevity dividend.


Jim O’Neill, SENS Research Foundation

Jim has advised, invested in, and nurtured more than seventy science and technology companies. While running the Thiel Foundation, he co-founded the Thiel Fellowship and helped create deep science fund Breakout Labs. Thiel Fellows have created more than $90 billion in equity value by founding companies including Freenome, Luminar, Figma, Upstart, OYO, Ethereum, Workflow, Fossa, and the Longevity Fund. Before moving to California, Jim helped lead the U.S. Department of Health and Human Services as the principal associate deputy secretary. His responsibilities included overseeing policy and regulations at NIH, FDA, and CDC and he led two major reforms of FDA. He also supported the creation of the Armed Forces Institute for Regenerative Medicine, served on the steering committee of the Biomedical Advanced Research and Development Authority, and represented the United States on the U.S. delegation to the World Health Assembly.​


Reason, Repair Biotechnologies

Reason is co-founder and CEO of Repair Biotechnologies. He is the founder and writer of Fight Aging!, a leading news website in the biotech community. Reason is also an active angel investor in the space. Previously, Reason was principal software engineer at technology startups. Reason has Masters degrees in Space Physics and Astrophysics.​

Joe Betts-LaCroix, CEO, Retro Biosciences

Following an academic background at Harvard, MIT, and Caltech, being an inventor on over 100 patents and applications, founding two prior companies with a combined 185 employees, spending 2 years as a part-time partner at Y Combinator, investing in and advising numerous biotechs, and publishing a Science paper in biophysics, Joe is now the CEO of Retro Biosciences, which uses high-throughput, high-dimensional approaches to develop therapies for diseases driven by the biology of aging.

Tina Wood, Collider Health

Tina is an ecosystem architect and works with organisations in both private and public sectors to accelerate innovation and transform health with sustainable impact at scale.

Morgan Levine, Yale University

Morgan Levine is a ladder-rank Assistant Professor in the Department of Pathology at the Yale School of Medicine and a member of both the Yale Combined Program in Computational Biology and Bioinformatics, and the Yale Center for Research on Aging. Her work relies on an interdisciplinary approach, integrating theories and methods from statistical genetics, computational biology, and mathematical demography to develop biomarkers of aging for humans and animal models using high-dimensional omics data. As PI or co-Investigator on multiple NIH-, Foundation-, and University-funded projects, she has extensive experience using systems-level and machine learning approaches to track epigenetic, transcriptomic, and proteomic changes with aging and incorporate this information to develop measures of risk stratification for major chronic diseases, such as cancer and Alzheimer’s disease. Her work also involves development of systems-level outcome measures of aging, aimed at facilitating evaluation for geroprotective interventions. A number of the existing biological aging measures she has developed are being applied in both basic and observational research.​

Gordan Lauc, University of Zagreb

Dr. Gordan Lauc is Professor of Biochemistry and Molecular Biology at the University of Zagreb Faculty of Pharmacy and Biochemistry. His laboratory performed the first large scale studies of the human plasma glycome (in 2009) and human IgG glycome (in 2011), which were the basis for the subsequent first GWAS of the human plasma and IgG glycomes. He was invited to lecture at numerous international conferences (including FEBS, EMBO, ASBMB, Glyco, etc), elected for visiting professor at the Johns Hopkins University, University of Edinburgh and Edith Cowan University in Perth. In 2011 he was inducted in the prestigious Johns Hopkins Society of Scholars. In 2007 Prof Lauc established Genos Ltd, a private research organisation accredited by the Croatian Ministry of Science, Education and Sport that currently has 28 employees, including 17 researchers. Genos was ranked as #1 in the 2013 survey of The Scientist magazine for “The best place to work for researches” in the category “Industry” and received a Charter of the Republic of Croatia (awarded by the President of Croatia) for an outstanding economic contribution to development of Croatia by commercialization of research results in 2014.​

Daniel Bojar

2020 Foresight Fellow, Harvard Wyss Institute

Daniel is the 2020 Foresight Fellow in Health & Longevity. His background is in structural biology, strengthened by a B.Sc. in biochemistry (University of Tuebingen, Germany, 2014) and a M.Sc. in biophysics (ETH Zurich, Switzerland, 2016) with distinction, enabled him to understand biological processes down to the atomic level. During his doctoral work with Dr. Martin Fussenegger at ETH Zurich, Daniel employed these fundamental insights to genetically re-engineer human cells for therapeutic purposes. Creatively using the principles of synthetic biology, he designed new proteins with a dedicated function – such as a novel caffeine receptor – and used these intricate tools to develop potent new cell-based therapies for diabetes mellitus and Parkinson’s disease. Further, Daniel was distinguished by several prestigious fellowships, such as the Excellence Scholarship and Opportunity Program of ETH Zurich and by the German Academic Scholarship Foundation, as well as in the form of a Selected Young Scientist at the 68th Lindau Nobel Laureate Meeting, an honor extended to the 600 most promising biomedical scientists worldwide. As a postdoctoral fellow with Dr. James J. Collins at the Wyss Institute for Biologically Inspired Engineering at Harvard University, Daniel harnesses the potency of cutting edge machine learning techniques to elucidate the biological functions of glycans since September 2019. Daniel was the first researcher to devise, develop, and apply methods derived from artificial intelligence to glycans and begin to tame their astounding complexity. In 2020, Daniel, was selected to be part of the prestigious Branco Weiss Fellowship – Society in Science 2020 Fellows, and as such was awarded $106,000 annually for five years to work on connecting machine learning and glycobiology, towards unveiling the inner workings of biology and facilitating biomedical therapies of tomorrow.


Joris Deelen

Max Planck Institute for Ageing

Joris Deelen is leading the research group on Genetics and Biomarkers of Human Ageing at the Max Planck Institute for Ageing Research. The group studies the genetic mechanisms underlying healthy ageing in humans by investigating the effect of genetic variants that are unique to long-lived families on the functioning of pathways implicated in ageing and/or age-related diseases. Moreover, they try to identify and validate biomarkers of healthy ageing using data from large-scale international collaborations of human studies.



Kristen Fortney


Kristen leads BIOAGE in its mission to develop a broad pipeline of therapies that target aging in order to increase healthspan and address chronic diseases. Kristen draws from a deep background in aging research and systems biology to develop BIOAGE’s data-driven approach to identify and target the molecular pathways that drive aging. Kristen received her PhD in Medical Biophysics from the University of Toronto, followed by postdoctoral training at Stanford University where she was a fellow of the Ellison Medical Foundation / American Federation for Aging Research. She has over 10 years of experience developing novel bioinformatics approaches for data-driven investigation into the mechanisms of aging and age-related disease, with 18 published papers spanning computational drug discovery, biomarkers of aging, and the genetics of exceptional human longevity.



Felix Faber

Cambridge University

Felix received a B.Sc. and a M.Sc. in physics at Linköping University in Sweden, followed by a Ph.D. in chemistry at the University of Basel. His master’s thesis, which was later published in the International Journal of Quantum Chemistry, was one of the first works that demonstrated successful learning of crystal formation energies. Felix developed machine learning techniques for modeling fundamental quantum mechanical properties. Such properties include energies, forces, and dipole moments of crystals and molecules. In one of his first Ph.D. projects, which was published in Physical Review Letters, Felix used a machine learning model to predict formation energies of almost 2 million Elpasolite crystal structures. This model was also used to identify around 90 potentially thermodynamically stable structures. He was also among those who pioneered the use of quantum mechanical operators directly on machine learning models, which results in improved performance and is a stepping stone towards universal machine learning modeling of quantum mechanical properties. Additionally, Felix dedicated parts of his Ph.D. to benchmarking and comparing the performance of different machine learning models. In one such example Felix and his team, in collaboration with scientists from google, performed one of the most comprehensive comparisons of different machine learning models to date. Felix envisions a research framework where these techniques could be harnessed to understand and model biological and materials systems of varying complexity. Such fundamental models could be used to develop therapeutics, as well as new materials tailored for exhibiting specific properties. To those ends, Felix recently started a postdoctoral fellowship at the University of Cambridge, where applying the models that he developed during his Ph.D. to discover new drugs and materials.


Margaretta Colangelo

Longevity Technology

Margaretta Colangelo is a native San Franciscan with over 30 years of experience working in the software industry in Silicon Valley. She has a deep and multifaceted understanding of business, science, and technology, and is highly adept at tracking and forecasting innovation in technology. She has published over 200 articles on AI , DeepTech, and Longevity.

Margaretta is Co-founder and CEO of Jthereum an enterprise Blockchain company and serves on the advisory boards of the AI Precision Health Institute at the University of Hawaii Cancer Center, NaNotics, Robots Go Mental. and on the Executive Board of Directors of the Bring Hope Humanitarian Foundation. She serves on the advisory board of the The Alliance for Longevity Initiatives and is a mentor to company founders in the Foresight Institute Biotech and Health Extension Accelerator.

Margaretta has been at the forefront of emerging technologies throughout her entire career. In the 1990s she was a core member of the team that developed the first Java based secure messaging software for stock trading platforms used by the world’s top multinational investment banks, and influenced important technical specifications and standards, including JDBC and JMS, that have helped advance the technology industry.

Margaretta’s articles have been published multiple times in Forbes, MIT Technology Review Italia, International Journal of Infectious Diseases, Health Management Journal, Outsourcing Pharma, Pharmaceutical Executive, Healthcare IT News, Bahrain Entrepreneur, Asian Robotics Review, and The American Journal of Translational Medicine. Margaretta publishes weekly newsletters on DeepTech, Longevity, and FinTech with hundreds of thousands of subscribers across multiple platforms. Margaretta speaks at AI conferences in the US, Mexico, Brazil, Singapore, Switzerland, Sweden, Portugal, Saudi Arabia, and Oman.


Petr Sramek

Petr Sramek is Managing Partner of and co-founder of He is a serial entrepreneur in deep tech for more than 30 years. Petr is building science, funding and business infrastructure to support faster adoption of health-span improving technologies. Petr was Entrepreneur in Residence at Singularity University, co-founder of the Platform on Artificial Intelligence at the Confederation of Industry, AI Startup Incubator founder and a Senator for the Czech Republic in the World Business Angels Investment Forum (WBAF). Petr is also the founder of the AI Awards project. Petr has been featured in the group of 28 AI leaders in the flagship World Intellectual Property Organization study.



Adam Gries

Material World

Adam is a serial entrepreneur and software engineer; he has sold four companies and built apps and games on iOS and Facebook reaching over 80 million users. Having always been passionate about education he is now building products that help people learn on mobile devices.


Joao Pedro De Magalhaes

University of Liverpool

Ageing has a profound impact on human society and modern medicine, yet it remains a major puzzle of biology. The goal of my work is to help understand the genetic, cellular, and molecular mechanisms of ageing. In the long term, I would like my work to help ameliorate age-related diseases and preserve health. No other biomedical field has so much potential to improve human health as research on the basic mechanisms of ageing. Please visit our lab website for further details about our work and publications, or see my TEDx talk.



Thomas Kalil

Schmidt Futures

Tom Kalil is Chief Innovation Officer at Schmidt Futures. In this role, Tom leads initiatives to harness technology for societal challenges, improve science policy, and identify and pursue 21st century moonshots.

Prior to Schmidt Futures, Tom served in the White House for two Presidents (Obama and Clinton), helping to design and launch national science and technology initiatives in areas such as nanotechnology, the BRAIN initiative, data science, materials by design, robotics, commercial space, high-speed networks, access to capital for startups, high-skill immigration, STEM education, learning technology, startup ecosystems, and the federal use of incentive prizes.
From 2001 to 2008, Kalil was Special Assistant to the Chancellor for Science and Technology at UC Berkeley. He launched a program called Big [email protected], which provide grants to student-led teams committed to solving important problems at home and abroad. In 2007 and 2008, Kalil was the Chair of the Global Health Working Group for the Clinton Global Initiative, where he developed new public and private sector initiatives in areas such as maternal and child health, under-nutrition, and vaccines.

Prior to joining the Clinton White House, Tom was a trade specialist at the Washington offices of Dewey Ballantine, where he represented the Semiconductor Industry Association on U.S.-Japan trade issues and technology policy. He also served as the principal staffer to Gordon Moore in his capacity as Chair of the SIA Technology Committee.

Tom received a B.A. in political science and international economics from the University of Wisconsin at Madison, and completed graduate work at the Fletcher School of Law and Diplomacy.



Karl Pfleger

Angel Investor, Aging

Karl Pfleger, PhD (Stanford CS, Machine Learning) now focuses on aging & longevity after a successful tech career (mySimon, Google). A long-time donor to the Buck Institute and SENS Foundation, he is also an angel investor who has backed over 15 aging-related startups. He is the creator of, a free public resource to track the commercialization progress of the aging biotech sector and related information.



James Peyer

Cambrian Bio

James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. He also serves as the Chairman of the Board of Sensei Biotherapeutics and holds multiple board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving major pharmaceutical clients. He earned his PhD in stem cell biology at University of Texas Southwestern Medical Center as a National Science Foundation Fellow and received his B.A. with special honors from the University of Chicago.



Matt Kaeberlein

 University of Washington

Dr. Matt Kaeberlein is a Professor of Pathology, Adjunct Professor of Genome Sciences, and Adjunct Professor of Oral Health Sciences at the University of Washington. His research interests are focused on basic mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life. He has published nearly 200 papers in top scientific journals and has been recognized by several prestigious awards, including a Breakthroughs in Gerontology Award, an Alzheimer’s Association Young Investigator Award, an Ellison Medical Foundation New Scholar in Aging Award, a Murdock Trust Award, a Pioneer in Aging Award, and the Vincent Cristofalo Rising Star in Aging Research.
His contributions have also been recognized with Fellow status in the American Association for the Advancement of Science, the American Aging Association, and the Gerontological Society of America. Dr.
Kaeberlein is a past President of the American Aging Association and has served on their Executive Committee and Board of Directors since 2012. He has also served as a member of the Board of Directors
for the Federation of American Societies for Experimental Biology and is currently the Chair of the Biological Sciences Section of the Gerontological Society of America. Dr. Kaeberlein serves on the editorial boards for several journals, including Science and eLife. Dr. Kaeberlein’s scientific discoveries have generated substantial public interest, with featured stories in major media outlets including appearing on the front
page of the New York Times, the Today Show, CNN, the UK Telegraph, Popular Science, Time Magazine, Scientific American, NPR, USA Today, National Geographic, and many others. In addition to his primary appointments, Dr. Kaeberlein is the co-Director of the University of Washington Nathan Shock Center of Excellence in the Basic Biology of Aging, the founding Director of the Healthy Aging and Longevity Research Institute at the University of Washington, and founder and co-Director of the Dog Aging Project.

Martin Borch Jensen

Gordian Bio

I work to make aging a good thing.

Our bodies have the capacity for rejuvenation, but we haven’t yet mastered the biology that makes this happen. Biology is full of feedback loops that cause non-linear responses, which makes it difficult to go from experimental observations to reliably producing specific physiological outcomes.

My focus is on developing technologies to interrogate the full network of aging processes inside living organisms. This includes multiplexed measurement of complex states, interpretable perturbations, and context-aware data models.

Previously, I was an academic working on a range of cellular mechanisms involved in aging: mitochondrial function, NAD metabolism, DNA damage signaling and other stress responses.

Brian Kennedy

Buck Institute

Dr. Kennedy earned his PhD from the Massachusetts Institute of Technology and is well known for his work during his graduate studies with Leonard Guarente, PhD, which led to the discovery that sirtuins (SIR2) modulate aging. He performed postdoctoral studies at the MGH Cancer Center associated with Harvard Medical School. From 2001 to 2010, he held a faculty position at the University of Washington. He was the president and CEO of the Buck Institute from 2010 to 2016 and remains a professor at the Institute. In addition, he is a visiting professor in medicine and healthy aging at National University Singapore, an adjunct professor in the Davis School of Gerontology at the University of Southern California, and an affiliate professor in the Department of Biochemistry at the University of Washington. Dr. Kennedy has published more than 160 papers in prestigious journals, including Cell, Science, and Nature. He serves as co-editor-in-chief of Aging Cell and is on the editorial board of a number of other scientific journals. He also routinely provides lectures to the public and is active in writing opinion pieces on aging in public media outlets around the world. More recently, Dr. Kennedy has become active in the biotechnology and pharmaceutical arena, serving as a consultant for several companies. He is currently on the board of directors of three companies, including acting as board chair of Mt. Tam Pharmaceuticals. He has also completed research projects for several biotechnology companies.

Vera Gorbunova

Co-director Rochester Aging Research Center, University of Rochester

Vera Gorbunova is an endowed Professor of Biology at the University of Rochester and a co-director of the Rochester Aging Research Center. Her research is focused on understanding the mechanisms of longevity and genome stability and on the studies of exceptionally long-lived mammals. Dr. Gorbunova earned her B.Sc. degrees at Saint Petersburg State University, Russia, and her Ph.D. at the Weizmann Institute of Science, Israel. Dr. Gorbunova pioneered comparative biology approach to study aging and identified rules that control the evolution of tumor suppressor mechanisms depending on the species lifespan and body mass. Dr. Gorbunova also investigates the role of Sirtuin proteins in maintaining genome stability. More recently the focus of her research has been on the longest-lived rodent species the naked mole rats and the blind mole rat. Dr. Gorbunova identified high molecular weight hyaluronan as the key mediator of cancer-resistance in the naked mole rat. Her work received awards from the Ellison Medical Foundation, the Glenn Foundation, American Federation for Aging Research, and from the National Institutes of Health. Her work was awarded the Cozzarelli Prize from PNAS, the prize for research on aging from ADPS/Alianz, France, Prince Hitachi Prize in Comparative Oncology, Japan, and Davey prize from Wilmot Cancer Center.

Gladyshev, Vadim N

Harvard University

Vadim N. Gladyshev is a professor at Harvard Medical School, Brigham and Women’s Hospital and an expert and pioneer in antioxidant/redox biology. He is known for his characterization of the human selenoprotein encoded by 25 genes. He has conducted studies on whether organisms can acquire cellular damage from their food; the role selenium plays as a micro-nutrient with significant health benefits. In 2013 he won the NIH Pioneer Award.


UC Berkeley

A key direction of my laboratory is to understand age-imposed and pathological changes in molecular compositions of systemic and local environments of adult stem cells and to calibrate these to health – youth. In the past few years this direction has been ramified into synthetic biology, CRISPR technologies, bio-orhtogonal proteomics and development of innovative digital bio-sensors that we collaboratively applied to the fields of aging and diagnostics of genetic diseases. Success in this research will improve our understanding of the determinants of homeostatic health and will enable novel rational approaches to treat a number of degenerative, fibrotic, metabolic and inflammatory diseases, as a class.

Liam Berryman

Nelumbo Inc

Liam is CEO and Co-Founder at Nelumbo, a company making physical products resistant to the elements, higher performance, and environmentally sustainable by creatively applying nanostructured materials. As CEO, Liam has led Nelumbo from garage start-up to an emerging company solving major problems for top tier clients. Nelumbo has received greater than $17M in private funding, is developing multiple products that provide breakthrough results for customers and the climate and is forging a defining culture to enable continued excellence in materials innovation and commercialization. Liam is also a personal advisor and mentor to select CEOs building big, unique ventures. He supports areas including deep technology and climate spaces, market analysis and financial planning, fundraising, clarifying story, public speaking, strategic deal structuring, and building growth teams.

Liam is a proud member of the Young President’s Organization (YPO), the Thiel Fellowship, and Forbes 30 under 30 for Energy. He has been a featured speaker at a variety of energy and climate conferences, including: Cleantech Forum, European Venture Fair, NREL Industry Growth Forum, Energy & Impact Symposium, Cleantech Open, Verge, Hive, National Investment Banking Association (NIBA), SinBerBEST, and the Cleantech University Prize.

Liam attended UC Berkeley for Chemical Engineering and worked as a lead researcher in the Design for Nanomanufacturing Lab. His research led to a novel synthesis process for polymer microspheres that was patented and later published in Progress in Organic Coatings.

Liam is a lifetime reader, runner, and surfer. He grew up on the coast of Northern California and currently lives in Berkeley.

Glen Weyl


Glen Weyl works to collaboratively envision, design, experiment with and organize around next generation political economic institutions. He serves at Microsoft’s Office of the Chief Technology Officer Political Economist and Social Technologist (OCTOPEST), where he helps design and implement technology ambitious corporate social commitments. He is Founder and Chair of the RadicalxChange Foundation, a non-profit that coordinates a global social movement for social technology. Previously he was 2007 Valedictorian of Princeton University, received his PhD in economics from there in 2008, was Junior Fellow at the Harvard Society of Fellows, Assistant Professor of Economics and Law at University of Chicago, co-author with Eric Posner of Radical Markets: Uprooting Capitalism and Democracy for a Just Society and co-author and technical lead of the Edmund J. Safra Center Rapid Response Task Force on Covid-19 that was a foundation of the Biden administration’s covid-19 response plan. In 2018, he was one of Bloomberg Businessweek’s 50 most influential people, WIRED’s 25 people shaping the next 25 years of technology and Coindesk’s 10 most influential people in blockchain.

Robin Hanson

George Mason University

Robin Hanson is associate professor of economics at George Mason University, and research associate at the Future of Humanity Institute of Oxford University. He has a doctorate in social science from California Institute of Technology, master’s degrees in physics and philosophy from the University of Chicago, and nine years experience as a research programmer, at Lockheed and NASA.

Professor Hanson has 4510 citations, a citation h-index of 33, and over ninety academic publications, including in Algorithmica, Applied Optics, Communications of the ACM, Economics Letters, Economica, Econometrica, Economics of Governance, Foundations of Physics, IEEE Intelligent Systems, Information Systems Frontiers, Innovations, International Joint Conference on Artificial Intelligence, Journal of Economic Behavior and Organization, Journal of Evolution and Technology, Journal of Law Economics and Policy, Journal of Political Philosophy, Journal of Prediction Markets, Journal of Public Economics, Maximum Entropy and Bayesian Methods, Medical Hypotheses, Proceedings of the Royal Society, Public Choice, Science, Social Epistemology, Social Philosophy and Policy, and Theory and Decision.

Oxford University Press published his book The Age of Em: Work, Love and Life When Robots Rule the Earth in June 2016, and his book The Elephant in the Brain: Hidden Motives in Everyday Life, co-authored with Kevin Simler, in January, 2018. Professor Hanson has 1007 media mentions, given 370 invited talks, and his blog has had eight million visits.

Professor Hanson has pioneered prediction markets, also known as information markets and idea futures, since 1988. He was the first to write in detail about creating and subsidizing markets to gain better estimates on a wide variety of important topics. He was a principal architect of the first internal corporate markets, at Xanadu in 1990, of the first web markets, the Foresight Exchange since 1994, of DARPA’s Policy Analysis Market, from 2001 to 2003, and of IARPA’s combinatorial markets DAGGRE and SCICAST from 2010 to 2015. Professor Hanson developed new technologies for conditional, combinatorial, and intermediated trading, and studied insider trading, manipulation, and other foul play. He has written and spoken widely on the application of idea futures to business and policy, and has advised many ventures. He suggests “futarchy”, a form of governance based on prediction markets.

Robin has diverse research interests, with papers on spatial product competition, health incentive contracts, group insurance, product bans, evolutionary psychology and bioethics of health care, voter information incentives, incentives to fake expertise, Bayesian classification, agreeing to disagree, self-deception in disagreement, probability elicitation, wiretaps, image reconstruction, the history of science prizes, reversible computation, the origin of life, the survival of humanity, very long term economic growth, growth given machine intelligence, and interstellar colonization. He coined the phrase “The Great Filter” to analyze why the universe looks so dead.

Cyrus Hodes

Global Partnership on AI


Cyrus most recently served as Advisor to the UAE Minister of Artificial Intelligence, currently working on projects that will positively impact the world through the use of AI and help shape the upcoming global governance of AI. Being passionate about drastically disruptive technologies, Cyrus previously led and still advises robotics and biotech ventures. In 2015, he co-founded the AI Initiative, which he managed by engaging a wide range of global stakeholders to study, discuss and help shape the governance of AI. The AI Initiative did, and continue to do so, through various international policy platforms (OEDC, HKS Forums, Japanese MIC, French Parliament, etc.) as well as AI ethics and safety initiatives. Cyrus spearheaded several projects using innovative tools (such as the Global Civic Debate and its multilingual collective intelligence platform on the governance of AI) and works at using AI and Machine Learning to tackle policy issues.

Cyrus is a member of three Committees (Policy, Well Being and General Principles) of the IEEE Global Initiative for Ethical Considerations in Artificial Intelligence and Autonomous Systems as well as a Senior Advisor to The Future Society. Cyrus was educated at Sciences Po Paris, where he later was a Lecturer, holds a M.A. (Hons) from Paris II University in Defense, Geostrategy and Industrial Dynamics and a M.P.A. for Harvard Kennedy School.